The New HPV Vaccination Policy in France

Lefèvre, Hervé; Moro, Marie-Rose; Lachal, Jonathan

doi:10.1056/nejmc1801036

Cited by 11 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this case, if the information is not always judged sufficient, vaccination appears nonetheless a normative process: vaccination becomes the rule. Contrary to other vaccinations that France made mandatory for infants in 2018 [25], the government continued its opportunistic vaccination system for HPV, based on individual decisions and, for those younger than 18 years, subject to parental authorization. This system requires that the person concerned or the decisionmaker have sufficient individual motivation.…”

Section: Discussionmentioning

confidence: 99%

HPV vaccination and sexual health in France: Empowering girls to decide

Lefèvre

Samain

Ibrahim

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

HPV vaccination and sexual health in France: Empowering girls to decide

Lefèvre

Samain

Ibrahim

et al. 2019

Vaccine

Self Cite

View full text Add to dashboard Cite

“…In France, hrHPV was detected in 13.7% of 3023 women with normal cytology, aged 25–64 years, attending cervical cancer screening. The HPV vaccine coverage was only 19% in 2016. Moreover, HPV infection carries a high cost in terms of disease burden and economic burden.…”

Section: Discussionmentioning

confidence: 99%

Transvaginal ultrasound probes are human papillomavirus‐free following low‐level disinfection: cross‐sectional multicenter survey

Heard

Roueli

Lafourcade

et al. 2019

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

Objectives To assess the frequency of detection of high‐risk human papillomavirus (hrHPV) on transvaginal ultrasound (TVS) probes and keyboards and evaluate operator compliance with national recommendations for prevention of cross‐infection during TVS. Methods This was a multicenter observational survey involving 46 public and private centers, in the Paris region of France, in which at least five consecutive TVS examinations were performed per day. We audited 676 TVS procedures. We recorded preventive hygiene actions undertaken by the operator at three stages: (1) during TVS; (2) during probe disinfection; and (3) during preparation of the probe for the next TVS. After probe disinfection, we collected one sample from the bare probe and one from the ultrasound keyboard; following probe preparation for the next examination, an additional sample was obtained from the covered probe. The samples were tested for presence of hrHPV DNA using the Cobas® 4800 System. Results We did not detect hrHPV DNA in samples collected from uncovered or covered probes (0%; 95% CI, 0.00–0.55%). Keyboard samples were positive for hrHPV in two cases (0.3%; 95% CI, 0.04–1.07%). During TVS, the operator avoided touching the keyboard with a hand that had touched the patient's vulva in 86% of cases and held the probe with a gloved hand in 68%. Before probe disinfection, the operator wore new gloves, or performed hand disinfection in 8% of cases. The probe disinfection technique used was adequate in 87% of cases, not performed at all in 12% and insufficient in 1%. Before preparing the probe for the next scan, the operators disinfected their hands or used new gloves in 81% of cases. The probe cover and the coupling gel used complied with recommendations in 98% and 46% of cases, respectively. Of the seven preventive hygiene actions recommended in national guidelines, all were performed in 2%, three to six in 95% and two in 3% of observations. In four (9%) centers, disinfection was not performed in over half the observations. Conclusions No evidence of hrHPV DNA was found on TVS probes and probe covers following low‐level disinfection, despite suboptimal compliance with hygiene guidelines. Routine TVS practice could be made easier and safer with a global approach to probe disinfection and hand hygiene. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

show abstract

“…Even in high-resource settings, elimination may prove a challenge, as exemplified by the situation in France, where HPV vaccine delivery has been challenging and uptake has remained low, at below 20% [15]. Experience from Sweden shows that, despite complete population registers and well-organized delivery, it is still challenging to achieve 90% coverage in population-based prevention programs [16].…”

Section: Opportunities and Challenges Posed By Resource Levelsmentioning

confidence: 99%

Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?

Sundström

Elfström

2020

PLoS Med

View full text Add to dashboard Cite

With major advances in understanding the infectious etiology of cervical cancer, preventive medicine has obtained highly promising new tools. Human papillomavirus (HPV) vaccines, together with a growing arsenal of HPV-based screening tests, have the potential to radically change public health but require diligent, large-scale implementation to reach the final goal: the elimination of cervical cancer. We reflect here upon the state of cervical cancer prevention globally as there have been several recent developments that will inform this implementation process.

show abstract

The New HPV Vaccination Policy in France

Cited by 11 publications

References 14 publications

HPV vaccination and sexual health in France: Empowering girls to decide

HPV vaccination and sexual health in France: Empowering girls to decide

Transvaginal ultrasound probes are human papillomavirus‐free following low‐level disinfection: cross‐sectional multicenter survey

Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?

Contact Info

Product

Resources

About